Revogene
Medical Supply
Meridian Bioscience Inc.
Total Payments
$166,059
Transactions
15
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $93,633 | 8 | 0 |
| 2020 | $61,073 | 5 | 0 |
| 2019 | $11,352 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $166,059 | 15 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluating prelimary performance and setting assay cut-offs for the Revogene SMART RP assay | Meridian Bioscience Inc. | $103,054 | 0 |
| Clinical evaluation of the molecular-based Revogene Enteric Panel Assay | Meridian Bioscience Inc. | $38,564 | 0 |
| Evaluating prelimary performance and setting assay cut-offs for the Revogene Enteric Panel Assay | Meridian Bioscience Inc. | $24,440 | 0 |
Top Doctors Receiving Payments for Revogene
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bloomington, IN | $166,059 | 15 |
Ad
Manufacturing Companies
- Meridian Bioscience Inc. $166,059
Product Information
- Type Medical Supply
- Total Payments $166,059
- Total Doctors 0
- Transactions 15
About Revogene
Revogene is a medical supply associated with $166,059 in payments to 0 healthcare providers, recorded across 15 transactions in the CMS Open Payments database. The primary manufacturer is Meridian Bioscience Inc..
Payment data is available from 2019 to 2021. In 2021, $93,633 was paid across 8 transactions to 0 doctors.
The most common payment nature for Revogene is "Unspecified" ($166,059, 100.0% of total).
Revogene is associated with 3 research studies, including "Evaluating prelimary performance and setting assay cut-offs for the Revogene SMART RP assay" ($103,054).